Experimental mRNA vaccine may protect against multiple Ebola viruses
Researchers at the Wuhan Institute of Virology in China have developed an experimental mRNA vaccine that protects mice against the Zaire, Sudan, and Bundibugyo strains of Ebola, including the Bundibugyo virus currently spreading in the Democratic Republic of the Congo and Uganda. The World Health Organization declared the outbreak a public health emergency of international concern, highlighting the urgent need for a broad-spectrum vaccine, as existing ones only target the Zaire strain.
A new mRNA vaccine developed by Yanfeng Yao and colleagues at the Wuhan Institute of Virology in China may offer long-term protection against multiple Ebola viruses, including the deadly Bundibugyo strain currently spreading in Central Africa. The vaccine, tested successfully in mice, targets the Zaire, Sudan, and Bundibugyo strains—all of which cause severe disease in humans—by combining mRNA encoding their glycoproteins and a shared nucleoprotein within a lipid nanoparticle. The World Health Organization declared the Bundibugyo outbreak in the Democratic Republic of the Congo and Uganda a public health emergency of international concern after over 600 infections were reported. While Zaire virus outbreaks have been more common, with over 28,000 cases between 2014 and 2016, no vaccines exist for the Bundibugyo or Sudan strains. The new vaccine uses a multivalent approach, addressing the challenge that each virus has distinct glycoproteins but shares nucleoproteins. In trials, vaccinated mice showed complete protection against Zaire and Sudan viruses and strong protection against Bundibugyo. Hamsters exposed to Sudan virus were also fully protected. The researchers caution that further testing in higher-order animals is needed before human trials, as rodent models do not fully replicate Ebola’s effects in humans. Experts like Robert Cross from the University of Texas Medical Branch praised the innovation but noted regulatory hurdles. Cross stated that multivalent vaccines require more complex approval processes, especially when targeting multiple pathogens. Adrian Esterman from Adelaide University called the study promising but emphasized the need for non-human primate testing, considered the gold standard for predicting human efficacy. The vaccine’s design combines mRNA sequences for each virus’s glycoproteins and the shared nucleoprotein, delivered via lipid nanoparticles to protect the genetic material until it reaches cells. While preliminary results are encouraging, the team stresses that additional research is necessary before human trials can begin.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.